Development and characterization of multiparticulate system as an alternative to unit dosage forms containing drugs with diverse release profiles

Author:

Dhanorkar Vandana,Shah Pranav

Abstract

Abstract Background Currently, the Bilayer tablets, Tablet in tablet and Inlay tablets composed of Glimepiride (GMP) and Pioglitazone (PGH) as immediate release part, and Metformin (MFH) as sustained-release part are available for the treatment of type II diabetes mellitus (T2DM). In these products, there is a possibility of the incomplete release of immediate release part (GMP and PGH) due to their entrapment into high viscosity gel barrier of MFH sustained-release part when drug product comes in contact with media. Therefore, the present study was aimed to deliver the above combination drugs in the form of hard gelatin capsules (as unit dosage form) containing MFH sustained-release (MFH-SR) pellets and immediate release pellets of PGH and GMP (PG-IR). Results The MFH-SR and GP-IR pellets, prepared by extrusion and spheronization technique, were optimized based on the drug content and % cumulative drug release. The MFH-SR pellets formulation (batch A6) has shown maximum drug content, and sustained-release of MFH similar to marketed glucophage tablet while, the GP-IR pellets formulation (batch B5) has displayed maximum drug contents and immediate release of GMP and PGH; thus, these batches were considered for further characterizations. The optimized MFH-SR and GP-IR formulations have shown particle sizes of 0.23 ± 0.0010 mm and 0.35 ± 0.0018 mm, respectively. Besides, the formulations exhibited good micromeritics properties. The in vivo pharmacokinetic study in rabbits has demonstrated comparable bioavailability of the drugs from pellets and the marketed formulations following oral administration. Further, the pellets were found to be stable for 6 months at 40 ± 2 °C/75% ± 5%RH. Conclusions The study results revealed that the multiparticulate systems with varied release profiles could be a promising approach to overcome drug release issues associated with the unit dosage forms.

Publisher

Springer Science and Business Media LLC

Reference21 articles.

1. Pouya S, Inga P, Paraskevi S. Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045 (2019) Results from the International Diabetes Federation Diabets Atlas, Diabets Research and Clinical Practice 11:57

2. Thangavel MV, Jayasutha J, Vishnu MC, Dasari H, Yalamanchili DT, Damodharan N (2017) Safety, efficacy, and bioavailability of fixed-dose combinations in type 2 diabetes mellitus: A systematic updated review. Curr Ther Res Clin Exp 84:4–9

3. Lobovitz HE (1991) Therapy for Diabetes mellitus and related disorders: American Diabetes Association. Alexandria, pp 114–22

4. Gowthamarajan K, Kulkarni GT (2003) Oral insulin fact or fiction. Resonance 8(5):38–46

5. Lee VHL, Robinson JR (1987) Influence of drug properties and routes of drug administration on the design of sustained and controlled release system. Control Drug Deliv Fund and Applic Marcel Dekker, New York, pp 3–94

Cited by 2 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3